

***Gymnema sylvestre*: THE SUGAR DESTROYER - BRIDGING ANCIENT AYURVEDA AND MODERN DIABETES THERAPEUTICS**

Ganga M¹, T. Shantappa¹ and Sangamesh²

¹University of Horticultural Sciences, Bagalkot 587104, Karnataka, India.

²Navsari Agricultural University, Gujarat 396 450, India.

*Corresponding author: gangamurthy2230@gmail.com

Accepted on Aug 18, 2026

Introduction

Diabetes mellitus has emerged as one of the most pressing global health challenges of the 21st century, with prevalence rising sharply across both developed and developing nations due to sedentary lifestyles, dietary shifts and increasing obesity rates. While conventional antidiabetic drugs including insulin, sulfonylureas, biguanides and newer classes such as SGLT2 inhibitors remain the mainstay of clinical management, their long-term use is often associated with adverse effects, secondary treatment failure and high costs, particularly burdensome in resource-limited settings. Against this backdrop, medicinal plants have regained significant scientific attention as sources of safe, affordable, and effective alternatives or adjuncts to synthetic antidiabetic therapy. Traditional systems of medicine, particularly Ayurveda, Siddha and various indigenous folk practices across India, have relied on plant-based remedies for the management of "madhumeha" (a Sanskrit term broadly corresponding to diabetes/glycosuria) for millennia. The World Health Organization has itself acknowledged the value of such traditional knowledge, encouraging systematic scientific evaluation of medicinal plants used in diabetes care. Among the vast repertoire of Indian antidiabetic flora, *Gymnema sylvestre* stands out as one of the most extensively documented and pharmacologically validated species (Fig. 1).




Fig. 1. Morphological features of *Gymnema sylvestre*

Botany and Distribution

G. sylvestre is a perennial woody climber (family Asclepiadaceae/Apocynaceae) distributed in India, Sri Lanka and other tropical regions (Fig. 2). The plant bears opposite, elliptic to ovate leaves (1.25–2.0 inches in length), small yellow flowers arranged in axillary umbellate cymes and terete, lanceolate follicles reaching up to 3 inches long. It is known by numerous vernacular names reflecting its widespread use across Indian linguistic regions Gurmar (Hindi), Meshashringi or Madhunashini (Sanskrit), Kavali (Marathi), Adigam or Cherukurinja (Tamil), Podapatri (Telugu) and Sannagerasehambu (Kannada), among others. Notably, the name "Gurmar," from which the genus name *Gymnema* is thought to derive, translates literally to "destroyer of sugar" a name earned through the plant's remarkable and scientifically documented ability to transiently suppress the perception of sweet taste when its leaves are chewed.



Fig. 2. Natural growth habit of *Gymnema sylvestre*

- **Traditional Uses:** Ayurveda recommends the plant mainly for diabetes (madhumeha). It is also traditionally used for obesity, dyspepsia, jaundice, asthma and inflammatory

disorders. Fresh leaves, powders and aqueous extracts are the most common preparations (Fig. 3).



Fig. 3. Value-added products of *Gymnema sylvestre*

- **Phytochemistry:** The major constituents are gymnemic acids, gymnemasaponins, gymnemasides and gurmardin peptide (Fig. 4.). Other compounds include flavonoids, triterpenes, sterols, tannins and phenolics that contribute to antioxidant and anti-inflammatory activities.




Fig. 4. Phytochemical constituents of *G. sylvestre*

- **Mechanism of Action:** Gymnemic acids block sweet taste receptors, inhibit intestinal glucose absorption, enhance insulin secretion, improve peripheral glucose utilization and may aid pancreatic β -cell recovery (Fig. 5).




Fig. 5. Mechanism of antidiabetic action

- **Pharmacological Activities:** The strongest evidence supports antidiabetic effects. Additional studies demonstrate lipid-lowering, anti-obesity, antioxidant, antimicrobial, hepatoprotective and anti-inflammatory activities, though many findings are from experimental models (Fig. 6).




Fig. 6. Pharmacological Activities of *G. sylvestre*

- **Clinical Evidence:** Human studies indicate improved fasting and postprandial blood glucose and reduced dependence on antidiabetic medication when *Gymnema* is used as an adjunct therapy (Fig. 7). However, most trials involve small sample sizes and short durations, preventing definitive conclusions. Standardized extracts appear more reliable than crude preparations.




Fig. 7. Clinical applications

- **Safety:** *Gymnema* is generally well tolerated at recommended doses. Possible adverse effects include hypoglycaemia, particularly with concurrent antidiabetic drugs. Rare cases of liver injury have been reported, highlighting the need for monitoring and standardized products.

Current Applications and Future Prospects

Gymnema is widely marketed as capsules, tablets, teas and nutraceuticals. Future research should focus on standardized formulations, large randomized clinical trials, pharmacokinetics and advanced delivery systems such as phytosomes and nanoparticles.

Conclusion

Gymnema sylvestre remains one of the most promising medicinal plants for diabetes management. Strong traditional use and extensive laboratory evidence support its therapeutic potential, but broader clinical validation and product standardization are essential before routine evidence-based clinical use.

References

Deciphering the Anti-Diabetic Potential of *Gymnema Sylvestre* Using Integrated Computer-Aided Drug Design and Network Pharmacology, 2025, Deciphering the anti-diabetic potential of *Gymnema sylvestre* using integrated computer-aided drug design and network pharmacology. *J. Cell. Mol. Med.*, 29: 1-15.

- NJCCM Authors, 2025, *Gymnema sylvestre* in modern medicine: A literature review on its role in diabetes and beyond. *NJCCM*, 1(1): 1-12.
- Plant Science Today Authors, 2025, *Gymnema* and diabetes: A review on well-known and underexplored species. *Plant Sci. Today*, 12: 1-14.
- Kashif M., et al., 2023, Unlocking the anti-diabetic potential of *Gymnema sylvestre*, *Trigonella foenum-graecum*, and their combination thereof: An in-vivo evaluation. *Food Sci. Nutr.*, 11: 7664-7672.
- Systematic Review Authors, 2024, A systematic review on *Gymnema sylvestre* in the obesity and diabetes management. *Pharmacie Globale*, 1: 1-20.
- Garcia Miranda D., Malagutti Tomé F., Viana Miguel M. M., Ferreira dos Santos Liberato S., Marcucci M. C., Vigerelli H., Pires Rodrigues F., Pacheco-Soares C., Godoi B. H., Carrouel F., Dias de Oliveira L. and de Paula Ramos L., 2025, *Gymnema sylvestre* as a potential anti-inflammatory and anti-biofilm agent against anaerobic infections: An in vitro study. *Plants*, 14(4): 497.
- National Institute of Diabetes and Digestive and Kidney Diseases, 2024, *Gymnema*. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, NIDDK, Bethesda: 1-8.
- Haideri M. H., Phanjaroen T., Khiaolaongam W., Boonchalaem T., Laoung-On J. and Chaipoot S., 2024, Effect of different extraction techniques on phenolic profile and phytochemical potential of *Gymnema inodorum* leaf extract. *Molecules*, 29(22): 5475.
- Kumar P., Rani S., Arunjyothi B., Chakrapani P. and Rojarani A., 2017, Evaluation of antidiabetic activity of *Gymnema sylvestre* and *Andrographis paniculata* in streptozotocin induced diabetic rats. *Int. J. Pharmacogn. Phytochem. Res.*, 9(1): 22-25.
- Nguyen D. Q., Nguyen D. L., Tran T. H. G., Nguyen K. T., Le T. N., Do T. T. T. and Nguyen H. H., 2024, Investigation of the effects of Huyet Rong germinated red rice on gene expression in diabetic mouse. *Vietnam J. Biotechnol.*, 22(4): 530-542.